Please assess the completion status of the following clinical trial:

Trial Title: Intravenous Immune Globulin (IVIG) Treatment Protocol in Kidney Transplant Patients

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* 12 years of age or older~* diagnosed with end stage renal disease~* currently receiving either hemodialysis or peritoneal dialysis~* active on the kidney or kidney/pancreas transplant list~* medical clearance of the kidney donor if live related transplant~* elevated panel reactive antibody (PRA) greater that 30% for 3 consecutive monthly tests and one positive crossmatch with a cadaveric donor while on the transplant waiting list~Exclusion Criteria:~* received IVIG within 6 months prior to enrollment~* HIV positive~* Positive Hepatitis Be-antigen and/or hepatitis B viral DNA~* Selective IgA deficiency or known antibodies to IgA~* Allergy to human immune globulin~* Pregnant or breast feeding

- Gender: ALL
- Minimum Age: 12 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Group 1 intravenous immune globulin (Type: OTHER): Intravenous immunoglobulin for: patients who do not have a living donor, have a PRA greater than 30% for 3 consecutive months, and have one positive crossmatch with a cadaveric donor while on kidney transplant waiting list
- Group 2 intravenous immune globulin (Type: OTHER): Intravenous immune globulin for patients who have living donors with positive crossmatch results.

Based on this trial design, predict the completion outcome and termination type (if applicable).